
需要安全验证




Facebook加入或登录 Facebook   邮箱或手机号密码忘记帐户？登录想加入 Facebook 吗？注册注册安全验证码请输入以下文本看不清楚上面的文字？换一个或播放语音验证信息框中文字：这是什么？安全验证这是一个标准的安全测试，用于阻止垃圾邮件制造者创建假帐户并向用户发送垃圾信息。提交中文(简体)English (US)日本語한국어Français (France)Bahasa IndonesiaPolskiEspañolPortuguês (Brasil)DeutschItalianoMessengerFacebook Lite用户地点游戏位置名人二手市场小组食谱彩色气球Instagram公司简介创建广告创建主页开发者招聘信息隐私权政策Cookie广告选项条款设置活动日志 Facebook © 2017





Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer - MarketWatch



















































Bulletin






Investor Alert























press release


					Nov. 29, 2016, 8:00 a.m. EST
				
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
























BOSTON, Nov 29, 2016 (GLOBE NEWSWIRE via COMTEX) --


                                        








Albireo Pharma, Inc.                 

/quotes/zigman/79940751/composite ALBO
-5.10%


, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Martha J. (Muffy) Carter as Chief Regulatory Officer. In this role, Ms. Carter will oversee all regulatory affairs for Albireo worldwide.        









"The wealth of regulatory and operational experience Muffy has accumulated during her four decades in the biopharmaceutical industry, including having successfully secured approval for an orphan drug in 36 countries, will be invaluable to Albireo," said Ron Cooper, President and Chief Executive Officer of Albireo. "Muffy will be instrumental in guiding A4250, our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), through the regulatory processes in the United States and Europe. We are delighted to welcome her to our management team."


                                        








Most recently, Ms. Carter was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID(R)/LOJUXTA(R) (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market. Prior to Aegerion, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Ms. Carter held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Ms. Carter holds a B.A. in biology from Northeastern University.


                                        








"I am thrilled to be joining Albireo as we ready A4250 for a potentially pivotal clinical trial in PFIC," said Ms. Carter. "I look forward to supporting the development of A4250 and Albireo's pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders."


                                        








About Albireo        
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.


                                        








Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit         www.albireopharma.com
.


                                        








Forward-Looking Statements -- Albireo        
This press release includes "forward-looking statements."  Forward-looking statements include statements, other than statements of historical fact, regarding Albireo's intentions, plans, beliefs, expectations or forecasts for the future, including regarding a potentially pivotal clinical trial of A4250 in PFIC or the ability of Albireo to successfully develop A4250 or any of its pipeline product candidates and obtain regulatory approval. Albireo uses words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "planned," "continue," "guidance," and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks and uncertainties, including, but not limited to: those described in the documents Albireo (f/k/a Biodel Inc.) has filed with the Securities and Exchange Commission, risks and uncertainties relating to: the conduct and results of Albireo's ongoing clinical trial of A4250 in children with chronic cholestasis; whether such ongoing clinical trial of A4250 will be sufficient to support advancement of A4250 into a pivotal clinical trial in PFIC; and the timing and success of submission, acceptance and approval of regulatory filings. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.


                                        








Source: Albireo Pharma, Inc.


                                        













        
        Investor Contact:
        Hans Vitzthum
        LifeSci Advisors, LLC.
        212-915-2568
        
        Media Contact:
        Heather Anderson
        6 Degrees
        980-938-0260
        handerson@6degreespr.com
        
        

















Copyright (C) 2016 GlobeNewswire, Inc. All rights reserved.
                    



/quotes/zigman/79940751/composite 





 Add to watchlist
                    
ALBO




Albireo Pharma Inc.


                US
                
                    : U.S.: Nasdaq
                
            




$
26.21



-1.41
-5.10%




Volume: 17,039
July 21, 2017 4:00p






P/E RatioN/A
Dividend YieldN/A




Market Cap$243.68 million
Rev. per Employee$874,154





 









 





































Most Popular





1.






The dark side of cruises






2.






The reason Jack Bogle doesn’t fly first class says everything about his investing legacy






3.






O.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family






4.






If you’re reading this, you have a 19.3% chance of being rich






5.






4 Luxury Pool Floats to Class Up Your Instagram








Find a Broker

Partner Center »























Featured Stories





Seeing America again through new eyes







How to dig yourself out of debt







Move over, Tesla? Karma unveils its hybrid sports car







The salary you need to afford a home in these 25 cities







Why OPEC will never cut production again













Log In




12:14 AM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:34pCharges dropped after ‘London Whale’ accused Jamie Dimon of making him a fall guy
7:41pGoodbye, Sean Spicer: Memorable Moments From the Podium  
7:18pHow to Fix Wall Street, and Bankers' Pay
6:59pAmazon, Whole Foods look to head off lengthy deal review
6:45pHawaii adopts emergency plan for North Korea missile attack
6:24p California Wildfire Destroys Homes Near Yosemite
6:20pSpicer Quits as Scaramucci Accepts White House Job
6:20pWhy you shouldn’t order ice on a flight, and other ‘dirty little secrets’ 
6:09pIf you’re reading this, you have a 19.3% chance of being rich
6:07p5 unfortunate reasons why millennials can’t have nice things (or save any money)
6:06pThis is the deadliest time of your life to put on weight
6:06pIf, like Sean Spicer, you suddenly walk out — what should you do next?
5:37pA History of Sears: Through Highs and Lows
5:13pAre you a money bully?
5:10pHow real-estate TV shows determine what home buyers look for and what to do if you decide to quit your job like Sean Spicer
5:07pBREAKINGWall Street's 'fear gauge'--the VIX--just logged its second-lowest close in history
5:06pWhy it might be time to invest in the companies Amazon is destroying
5:06pThis is what should really worry you about stocks
5:04pBeware of the curse of the number 7 in the stock market 
5:00pS&P 500, Nasdaq post weekly gains as stock market finishes session lower
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15




























































Albireo News: Martha J. Carter joined as Chief Regulatory Officer





































































Sign In > 

Sign In >








 You need to sign
						in to access your {{page}}
					


{{autErrorMsg}}
sign in >
New to Owler? Register here >















					Your sign in link has been sent to: {{email}}


					This might take a minute. If you don't receive it, first check
					spam/junk folders, then add notifications@owler.com and
					notifications@owler-inc.com to your contacts list and request the link again
						>
































            You have just joined {{count}} of your colleagues at {{name}} who read the Owler Daily Snapshot everyday.
        

            You have just joined over 1 million business professionals on Owler who read the Daily Snapshot everyday.
        

            Go to 'My Portfolio' to follow the companies that matter to you to customize your Daily Snapshot.
        















The Full Event





Martha J. Carter joined as Chief Regulatory Officer





Source: GlobeNewswire
Read full article >

















Martha J. Carter joined as Chief Regulatory Officer >




GlobeNewswire

ARTICLE >










null >




null

ARTICLE >










Albireo Expands Team, Appoints As Chief Regulatory Officer   >



Life Sciences Jobs ...

BioSpace

ARTICLE >










Press Release: Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer >




GlobalNewswire

ARTICLE >








					More on This Event
					View All {{feeds[0].company_name}} News >









{{feed.source|ellipsis:22}}

{{feed.title|ellipsis:65}} >
{{feed.article_description|ellipsis:200}}






Latest Events about {{timeLineStories[0].company_name}}






{{timeLineStories[0].feed_time}}








	                    		{{feed.title|ellipsis:80}}
	                    	

	                    		{{feed.title|ellipsis:80}}
	                    	



{{feed.title|ellipsis:80}}


{{feed.title|ellipsis:80}}



{{feed.title|ellipsis:80}}


{{feed.feed_time}}




{{timeLineStories[timeLineStories.length-1].feed_time}}




About {{companyDetails.shortName}}
            View Full {{companyDetails.shortName}} Profile >



{{companyDetails.shortName}} At-a-Glance










{{ceoData.job_title}}
{{ceoData.job_title}}

CEO
{{ceoData.first_name}} {{ceoData.last_name}}
Unknown


Approval Rating:

{{ceoInsightDetails.insight_info.consensus}}%
--
{{ceoInsightDetails.insight_info.totalVotes}} Votes
{{ceoInsightDetails.insight_info.totalVotes}} Vote
{{ceoInsightDetails.insight_info.totalVotes}} Votes
{{ceoInsightDetails.insight_info.totalVotes}} Vote



Approval Rating:
--


Approval Rating:
--















Founded:
{{companyDetails.founded}}
--


Headquarters:

{{companyDetails.hqAddress.street1}},
{{companyDetails.hqAddress.street2}},
{{companyDetails.hqAddress.city}},
 {{companyDetails.hqAddress.state}},
{{companyDetails.hqAddress.country}}
--



Status:
{{companyDetails.ownership}}{{companyDetails.statusInfo.status}}, {{companyDetails.statusInfo.status}} of {{companyDetails.statusInfo.parent_name}} {{companyDetails.statusInfo.parent_name}} >of {{companyDetails.statusInfo.parent_name}} {{companyDetails.statusInfo.parent_name}} >{{companyDetails.statusInfo.status}}, {{companyDetails.exchange}}, {{companyDetails.ticker}}--


Industry Sector:




 {{sector.sector_name}} ({{sector.sector_company_count}})


--









Key Stats 



Estimated Revenue(TTM)


${{reve_estimate.value}}{{reve_estimate.denomination}}
less than$1M
${{reve_estimate.value}}{{reve_estimate.denomination}}*
less than$1M*
${{reve_estimate.value}}{{reve_estimate.denomination}}
less than$1M


--


--






ConsensusTrend:












Revenue

${{reve_estimate.value}}{{reve_estimate.denomination}}
--


Trailing Twelve Months
Data is publicly sourced & uneditable





Estimated Employees
Estimated Employees


{{insightDetails.EMPLOYEE.insight_info.consensus | number}}
{{insightDetails.EMPLOYEE.my_estimate | number }}*
{{insightDetails.EMPLOYEE.insight_info.consensus | number}}


--
--
--


--

{{insightDetails.EMPLOYEE.insight_info.totalVotes}} Votes





ConsensusTrend:














Not Enough Consensus







Employees

{{revenueEmpHistory.total_employees | number}}

                		--
                	


Data is publicly sourced & uneditable





Headquarters






{{companySummary}}















 

SIGN IN  

Sign in with your email address:



 Sign in via  LinkedIn instead >


We no longer support sign in via Facebook or Twitter. Please use your email instead.


THANKS!
We sent you a link to sign in.
			Please check your inbox shortly.


OK!

If you don't receive the email, please be sure to check your spam folder. Questions?





You'll need to register to do that!


REGISTER WITH FACEBOOK CREDS
REGISTER WITH LINKEDIN CREDS
REGISTER WITH GOOGLE CREDS
NEW REGISTRATION


Registering will allow you to sync up the companies you are following with your phone & desktop AND allow you to update company data and 
				take surveys on Owler.com.






Sign up:










Enter your business email 





Domain is not valid. Please use a valid email address




 

























Email Address:



 
















			We have sent an email to  
			containing an activation link. Please follow the link to complete
			your registration. If you don't see it immediately, check your spam
			folder.
		

Ok
Resend






Thanks for registering!

PLEASE NOTE:






You have been assigned Change above if desired as a screen name.
You must confirm your email address to access all features of Owler.








Thank you for registering!

PLEASE NOTE:






You have been assigned Change above if desired as a screen name.














Owler needs your email address...












			We have resent an email to  
			containing an activation link. Please follow the link to complete
			your registration. If you don't see it immediately, check your spam
			folder.
		





			Your account has been locked. Please contact support@owler.com if you feel this is an error.
		





THANKS! JUST TWO MORE THINGS...







1. We've assigned you a random screen name: 
(please change as desired)
2. Please change your random password: 



















Albireo Expands Team, Appoints Martha J. Carter As Chief Regulatory Officer - TheStreet




































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Albireo Expands Team, Appoints Martha J. Carter As Chief Regulatory Officer






GlobeNewswire



Nov 29, 2016 8:00 AM EST













 




























































 BOSTON, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Martha J. (Muffy) Carter as Chief Regulatory Officer. In this role, Ms. Carter will oversee all regulatory affairs for Albireo worldwide. "The wealth of regulatory and operational experience Muffy has accumulated during her four decades in the biopharmaceutical industry, including having successfully secured approval for an orphan drug in 36 countries, will be invaluable to Albireo," said Ron Cooper, President and Chief Executive Officer of Albireo. "Muffy will be instrumental in guiding A4250, our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), through the regulatory processes in the United States and Europe. We are delighted to welcome her to our management team." Most recently, Ms. Carter was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID®/LOJUXTA® (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market. Prior to Aegerion, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Ms. Carter held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Ms. Carter holds a B.A. in biology from Northeastern University. "I am thrilled to be joining Albireo as we ready A4250 for a potentially pivotal clinical trial in PFIC," said Ms. Carter. "I look forward to supporting the development of A4250 and Albireo's pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders."  



 








 































































 











Trending


Amazon 'Deceptive' Pricing Probe by the FTC Could Be the Start of a Government Siege


Sears Just Surrendered to Amazon With Kenmore Deal


Don't Sleep on General Electric's Cheap Stock Price


Chipotle's New Health Scare Could Trigger a 'Hindenburg Scenario', Expert Says


Bored With Cream and Sugar? You Can Now Add Weed to Your Morning Joe











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 























 













 













 




	Albireo Expands Team Appoints Martha J Carter As Chief Regulatory Officer













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Albireo (ALBO) Expands Team, Appoints Martha J. Carter As Chief Regulatory Officer  











Tweet








11/29/2016 8:05:50 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs



BOSTON, Nov.  29, 2016  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Martha J. (Muffy) Carter as Chief Regulatory Officer. In this role, Ms. Carter will oversee all regulatory affairs for Albireo worldwide. “The wealth of regulatory and operational experience Muffy has accumulated during her four decades in the biopharmaceutical industry, including having successfully secured approval for an orphan drug in 36 countries, will be invaluable to Albireo,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Muffy will be instrumental in guiding A4250, our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), through the regulatory processes in the United States and Europe. We are delighted to welcome her to our management team.” Most recently, Ms. Carter was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID®/LOJUXTA® (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market. Prior to Aegerion, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Ms. Carter held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Ms. Carter holds a B.A. in biology from Northeastern University. “I am thrilled to be joining Albireo as we ready A4250 for a potentially pivotal clinical trial in PFIC,” said Ms. Carter. “I look forward to supporting the development of A4250 and Albireo’s pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders.” About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. Forward-Looking Statements — AlbireoThis press release includes “forward-looking statements.”  Forward-looking statements include statements, other than statements of historical fact, regarding Albireo’s intentions, plans, beliefs, expectations or forecasts for the future, including regarding a potentially pivotal clinical trial of A4250 in PFIC or the ability of Albireo to successfully develop A4250 or any of its pipeline product candidates and obtain regulatory approval. Albireo uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks and uncertainties, including, but not limited to: those described in the documents Albireo (f/k/a Biodel Inc.) has filed with the Securities and Exchange Commission, risks and uncertainties relating to: the conduct and results of Albireo’s ongoing clinical trial of A4250 in children with chronic cholestasis; whether such ongoing clinical trial of A4250 will be sufficient to support advancement of A4250 into a pivotal clinical trial in PFIC; and the timing and success of submission, acceptance and approval of regulatory filings. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Source: Albireo Pharma, Inc.  Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com







                Read at
                BioSpace.com







Related News
How Boston Biotech Albireo (ALBO) Goes Public In Unusual Fashion  President-Elect Trump Set to Debut Dream Team for Healthcare Reform  Albireo (ALBO)’s Lead Product Candidate For Orphan Pediatric Liver Disease Accepted Into EMA's PRIME Program
  French Cancer Specialist Innate Pharma (IPH.PA ) Can Remain Independent, For Now: CEO  Albireo (ALBO) Completes Transaction With Biodel (BIOD) To Create Publicly Traded Company Focused On Orphan Pediatric Liver Diseases
  Trump Names Rep. Tom Price as Next HHS Secretary  Boston's Albireo Reports Positive Late Stage Data Results for Elobixibat  How Donald Trump Could Disrupt the FDA Boston's Albireo Taps Alexion (ALXN) Exec as New CMO  'Retired' Former Novartis AG (NVS) R&D Cancer Head Returns for a New Gig at the Dana-Farber Cancer Institute 




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Albireo




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 
































Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer (NASDAQ:ALBO)





























 



Facebook
Google
LinkedIn
Twitter
Email
RSS





Nov 29, 2016



 Previous Release | Next Release 


PDF

Add to Briefcase
File is in Briefcase



Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer

BOSTON, Nov.  29, 2016  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Martha J. (Muffy) Carter as Chief Regulatory Officer. In this role, Ms. Carter will oversee all regulatory affairs for Albireo worldwide.
"The wealth of regulatory and operational experience Muffy has accumulated during her four decades in the biopharmaceutical industry, including having successfully secured approval for an orphan drug in 36 countries, will be invaluable to Albireo," said Ron Cooper, President and Chief Executive Officer of Albireo. "Muffy will be instrumental in guiding A4250, our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), through the regulatory processes in the United States and Europe. We are delighted to welcome her to our management team." Most recently, Ms. Carter was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a 
biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID®/LOJUXTA® (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market. Prior to Aegerion, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Ms. Carter held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Ms. Carter holds a B.A. in biology from Northeastern University. "I am 
thrilled to be joining Albireo as we ready A4250 for a potentially pivotal clinical trial in PFIC," said Ms. Carter. "I look forward to supporting the development of A4250 and Albireo's pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders." About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. Forward-Looking Statements — AlbireoThis press release includes "forward-looking statements."  Forward-looking statements include statements, other than statements of historical fact, regarding Albireo's intentions, plans, beliefs, expectations or forecasts for the future, including regarding a 
potentially pivotal clinical trial of A4250 in PFIC or the ability of Albireo to successfully develop A4250 or any of its pipeline product candidates and obtain regulatory approval. Albireo uses words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "planned," "continue," "guidance," and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks and uncertainties, including, but not limited to: those described in the documents Albireo (f/k/a Biodel Inc.) has filed with the Securities and Exchange Commission, risks and uncertainties relating to: the conduct 
and results of Albireo's ongoing clinical trial of A4250 in children with chronic cholestasis; whether such ongoing clinical trial of A4250 will be sufficient to support advancement of A4250 into a pivotal clinical trial in PFIC; and the timing and success of submission, acceptance and approval of regulatory filings. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Source: Albireo Pharma, Inc.  
Investor Contact:

Hans Vitzthum

LifeSci Advisors, LLC.

212-915-2568



Media Contact:

Heather Anderson

6 Degrees

980-938-0260

handerson@6degreespr.com


Source: Albireo, Inc.

News Provided by Acquire Media








 




















Home


Site Map


About Us


Media Kit


Contact Us


Help











Register Now
Why register?


Login
























							 The leading web portal for pharmacy resources, news, education and careers
						

							July 21, 2017
						










News

Drug Delivery Systems
Drugstores
FDA Final Approvals
Front Page Healthcare News
Generic Drugs
Hospital Industry
Internet Pharmacy
IT in Healthcare
Medicare & Medicaid
Over-the-Counter Drugs
Pharm Industry Trends and Policy
Pharmaceutical Development
Pharmaceutical Industry


Pharmacy Careers

Pharmacist
Pharmacy Technician
Pharmacy Job Board
Job Placement Help
So you want a job as a pharmacist?
Start your career as a:pharmacy technician


Resources

Boards of Pharmacy
Drug Database
FDA Resources
Pharmacy Associations
Pharmacy Journals
Pharmacy Newsletters
State Associations
More...


Education

Certification Courses
Continuing Education
Disease State Management
International Pharmacy Schools
Live On-Line CE
Pharmacy Schools
Pharmacy Technician Training


Business

Advertising Information / Media Kit
Consulting
Contact Us
Pharmacy Marketing


Marketplace

Drug Manufacturers
Drug Wholesalers
Automation and Robotics
Compounding Supplies
Medication & Supply Dispensing Systems
Tablet & Capsule Counters
Wholesalers & Distributors
More...
























Pharmacy Choice - Pharmaceutical News - Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer - July 21, 2017
Pharmacy News Article






							 11/29/16 - Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
						



BOSTON, Nov.  29, 2016  (GLOBE NEWSWIRE)  Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Martha J. (Muffy) Carter as Chief Regulatory Officer. In this role, Ms. Carter will oversee all regulatory affairs for Albireo worldwide.
The wealth of regulatory and operational experience Muffy has accumulated during her four decades in the biopharmaceutical industry, including having successfully secured approval for an orphan drug in 36 countries, will be invaluable to Albireo, said Ron Cooper, President and Chief Executive Officer of Albireo. Muffy will be instrumental in guiding A4250, our lead product candidate in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), through the regulatory processes in the United States and Europe. We are delighted to welcome her to our management team. Most recently, Ms. Carter was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID/LOJUXTA (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market. Prior to Aegerion, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Ms. Carter held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Ms. Carter holds a B.A. in biology from Northeastern University. I am thrilled to be joining Albireo as we ready A4250 for a potentially pivotal clinical trial in PFIC, said Ms. Carter. I look forward to supporting the development of A4250 and Albireo's pipeline of bile acid modulators as we work to bring much needed new treatment options to patients suffering from orphan liver diseases and gastrointestinal disorders. About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. Forward-Looking Statements  AlbireoThis press release includes forward-looking statements. Forward-looking statements include statements, other than statements of historical fact, regarding Albireo's intentions, plans, beliefs, expectations or forecasts for the future, including regarding a potentially pivotal clinical trial of A4250 in PFIC or the ability of Albireo to successfully develop A4250 or any of its pipeline product candidates and obtain regulatory approval. Albireo uses words such as anticipates, believes, plans, expects, projects, future, intends, may, will, 'should, could, estimates, predicts, potential, planned, continue, guidance, and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks and uncertainties, including, but not limited to: those described in the documents Albireo (f/k/a Biodel Inc.) has filed with the Securities and Exchange Commission, risks and uncertainties relating to: the conduct and results of Albireo's ongoing clinical trial of A4250 in children with chronic cholestasis; whether such ongoing clinical trial of A4250 will be sufficient to support advancement of A4250 into a pivotal clinical trial in PFIC; and the timing and success of submission, acceptance and approval of regulatory filings. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Source: Albireo Pharma, Inc.  
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com

Source: Albireo, Inc.
						





2016 GlobeNewswire, Inc.



















		Pharmacy News Index
		






						  Drug Delivery Systems




						  Drugstores




						  FDA Final Approvals




						  Front Page Healthcare News




						  Generic Drugs




						  Hospital Industry




						  Internet Pharmacy




						  IT in Healthcare




						  Medicare & Medicaid




						  Over-the-Counter Drugs




						  Pharm Industry Trends and Policy




						  Pharmaceutical Development




						  Pharmaceutical Industry













LIVE ONLINE CE









Jul 23: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management





Jul 24: What's New? New Treatments for Type 2 Diabetes





Jul 26: Management of Schizophrenia & Acute Agitation





Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis





Jul 31: Obesity Management: Overview of Pharmacotherapy





Click for entire Webinar Calendar










			Special Announcement
		















				Free Membership
				



					Enjoy Drug Search, industry newsletters and more...
					










			Nursing Jobs
		



			Are you a nurse looking for a job?
			Check out the Nursing Job Source.
			Your number one choice for nursing jobs.
		
















			Websites  »  RxCareerCenter.com • RxSchool.com • ClubStaffing.com • NursingJobSource.com • RN.com








NEWS
Drug Delivery Systems
Drugstores
FDA Final Approvals
Front Page Healthcare News
Generic Drugs
Hospital Industry
Internet Pharmacy
IT in Healthcare
Medicare & Medicaid
Over-the-Counter Drugs
Pharm Industry Trends and Policy
Pharmaceutical Development
Pharmaceutical Industry


CAREERS
Pharmacist
Pharmacy Technician
Pharmacy Job Board
Jobs Placement Help
So you want a job as a pharmacist?
Start your career as apharmacy technician


RESOURCES
Boards of Pharmacy
Drug Databases
FDA Resources
Pharmacy Associations
Pharmacy Journals
Pharmacy Newsletters
State Associations
More...


EDUCATION
Certification Courses
Continuing Education
Disease State Management
International Pharmacy Schools
Live On-Line CE
Pharmacy CE
Pharmacy Schools
Pharmacy Tech Training


BUSINESS
Advertising Information
Consulting
Contact Us
Pharmacy Marketing


MARKETPLACE
Drug Manufacturers
Drug Wholesalers
Automation and Robotics
Compounding Supplies
Medication & Supply   Dispensing Systems
Tablet & Capsule Counters
Wholesalers & Distributors
More...


MOST POPULAR
Pharmacy Jobs
Continuing Education
FDA Resources
Drug Information
Pharmacy News
Disease States
Pharm Tech Training






				Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement 
				888-682-4415 









 



Carters Martha (Toddler/Little Kid) at 6pm.com

























































Free shipping
any 2+ items or $50+!
See Details





1.888.676.2660


6AM - 8PM PST







Log InLogout

My Account


















Close 






1.888.676.2660


6AM - 8PM PST




Shoes






Women's


Sandals


Sneakers


Flats


Heels


Clogs & Mules


View all...




Men's


Sneakers


Sandals


Boat Shoes


Loafers


Oxfords


View all...






The Sandals Shop




The Luxury Shop




Summer Shoe Trends
















Clothing






Women's


Dresses


Shirts & Tops


Swimwear


Shorts


View all...




Men's


Shirts & Tops


Shorts


Swimwear


Pants


View all...




Specialty Shops


Juniors' Shop


Swim Shop


Athletic Shop


Outdoor Shop


Luxury Shop


Plus Size Shop















Bags






All Bags


Handbags


Backpacks


Wallets & Accessories


Luggage


View all...




Top Styles


Cross Body


Totes


Shoulder Bags


Satchels


Clutches




Top Brands


Coach


Tommy Hilfiger


Valentino Bags by Mario Valentino


Steve Madden


Frye















Accessories






All Accessories


Sunglasses


Hats


Watches


Jewelry


Belts




Sunglass Styles


Aviators


Oval


Rectangular


Cat Eye


View all...




Top Brands


Oakley


Spy Optic


Under Armour


GUESS


Columbia















Women's






Shoes


Sandals


Sneakers


Flats


Heels


View all...




Clothing


Dresses


Shirts & Tops


Activewear


Swimwear


View all...






Handbags




Eyewear




Watches




Jewelry




Accessories





Specialty Sizes


Plus Size


Petite


Juniors















Men's






Shoes


Sneakers


Sandals


Boat Shoes


Loafers


View all...




Clothing


Shirts & Tops


Shorts


Activewear


Swimwear


View all...






Bags




Eyewear




Accessories
















Kids'






Boys


Shoes


Clothing


Accessories


View all...




Girls


Shoes


Clothing


Accessories


View all...




Shop by Age


Infant


Toddler


Little Kid


Big Kid















Clearance


Brands






Featured Brands


COACH


Brooks


Nine West


ASICS


Nike


UGG


Oakley


SKECHERS


Cole Haan




Brand Index


#


A


B


C


D


E


F


G


H


I


J


K


L


M


N


O


P


Q


R


S


T


U


V


W


X


Y


Z










 Need Help?


 














Up To 60% Off MSRP

Shop Now




 



 








 Back
|
 Shoes
 Sneakers & Athletic Shoes
 Carters









Carters Martha (Toddler/Little Kid)






 


























































Product Information


SKU: #8737336


Stay golden pony girl!
Textile upper.
Lace-up closure.
Stitch detail.
Soft fabric lining and footbed.
Rubber outsole.
Imported.
Measurements:

 Weight: 4 oz


Product measurements were taken using size 8 Toddler, width M. Please note that measurements may vary by size.






 






 


 





MSRP $34.00
$19.99


Color:

Gold



Size (Size Chart):



Select a Size
7 Toddler
8 Toddler
9 Toddler
11 Little Kid
12 Little Kid





Width:


M



Add to Shopping Bag



Add to Favorites 



Share:







Tweet




Pin It



Email



 
















Shop with Confidence


Shopping on 6pm.com is Safe

Safe Shopping Guarantee


























Shipping
Free shipping when you buy 2 or more items, or 1 item over $50!


See Details









Return Policy
6pm.com will be happy to accept a return within 30 days of the date of purchase.


Learn More

























Customer Service


Safe Shopping Guarantee


Forgot Password


Shipping Rates


Return Policy


FAQs


Contact Info




Shopping


Womens


Mens


Kids


Brands




My Account


Login/Register


My Account


Order Status


Order History


Print An Invoice


Track My Order




Information


About


Site Map


Coupons


Find us on:









Resources


Associates Program



How Do You Like Our Website?
We'd like to get your feedback.




Terms Of Use
Privacy Policy
Interest-Based Ads
Welg



© 2009-2017 Zappos.com, Inc. or its affiliates, 400 East Stewart Avenue. Las Vegas NV 89101
6pm.com is operated by Zappos IP, Inc. Products on 6pm.com are sold by 6pm.com, LLC.
e-Gift Cards on 6pm.com are sold by ACI Gift Cards, Inc.

For premier service, selection, and shipping, visit Zappos.com — your one-stop shop for the latest in Shoes, Sandals, Dresses, Jeans and more!


For luxury and designer styles, visit Zappos Luxury.




 






 

















403 Forbidden

Forbidden
You don't have permission to access /product/carter-s-martha-girls-infant-toddler-/1060769-1
on this server.

Apache Server at www.masseys.com Port 80

